A dose-ranging, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of 4 doses of imeglimin after 24 weeks of treatment in subjects with type 2 diabetes mellitus
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Poxel
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.
- 06 Jun 2015 According to a Poxel media release, data from this trial were selected for presentation on a Guided Audio Poster Tour in addition to the main poster presentation.
- 06 Jun 2015 Results (full analysis of the trials top line data as announced in December 2014) were presented at the American Diabetes Association (ADA) 75th Scientific Sessions, according to a Poxel media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History